The Ehlers Danlos Syndrome (EDS) disorders are a group of heritable connective tissue disorders generally characterized by joint hypermobility and variable manifestations involving the skin, soft tissue and other body systems. Although considered rare, the true prevalence is anticipated to be much higher than currently appreciated, primarily due to lack of awareness among the healthcare community. The most common subtype of EDS is likely hypermobile EDS (hEDS), the only subtype relying on a clinical diagnosis and currently without a defined genetic basis. Early diagnosis of EDS is important to prevent and reduce disease-related complications, as well as inappropriate medical care, especially given the presence of multisystem involvement of disease and frequency of un/misdiagnosed patients.
There is no cure for EDS and many interventions to mitigate disease-related manifestations have not been rigorously evaluated. Moreover, the prevalence of certain subtypes like hEDS remain underappreciated, as does the mechanism driving hEDS-related pathology and co-morbid conditions, such as orthostatic intolerance or immunologic dysfunction. A collective research topic presenting articles related to understanding disease prevalence, multisystem manifestations, best treatment and management practices, and even future goals to fill current knowledge gaps will help to enable healthcare provider awareness and ultimately improve patient outcomes.
A wide variety of manuscript types will be considered and submissions may take the form of original and brief research reports, randomized trials, review articles, perspectives, community case studies or others. Studies linking basic research to clinical practice or translation to new therapies or diagnositic tools will be prioritized. Accepted articles are anticipated to span across a variety of clinical disciplines or sections. Single case reports will not be considered. In addition, manuscripts focusing on hEDS will be prioritized, especially those providing insight into frequently encountered co-morbid conditions; however, submissions related to any EDS subtype as well as Hypermobility Spectrum Disorder will be considered.
The Ehlers Danlos Syndrome (EDS) disorders are a group of heritable connective tissue disorders generally characterized by joint hypermobility and variable manifestations involving the skin, soft tissue and other body systems. Although considered rare, the true prevalence is anticipated to be much higher than currently appreciated, primarily due to lack of awareness among the healthcare community. The most common subtype of EDS is likely hypermobile EDS (hEDS), the only subtype relying on a clinical diagnosis and currently without a defined genetic basis. Early diagnosis of EDS is important to prevent and reduce disease-related complications, as well as inappropriate medical care, especially given the presence of multisystem involvement of disease and frequency of un/misdiagnosed patients.
There is no cure for EDS and many interventions to mitigate disease-related manifestations have not been rigorously evaluated. Moreover, the prevalence of certain subtypes like hEDS remain underappreciated, as does the mechanism driving hEDS-related pathology and co-morbid conditions, such as orthostatic intolerance or immunologic dysfunction. A collective research topic presenting articles related to understanding disease prevalence, multisystem manifestations, best treatment and management practices, and even future goals to fill current knowledge gaps will help to enable healthcare provider awareness and ultimately improve patient outcomes.
A wide variety of manuscript types will be considered and submissions may take the form of original and brief research reports, randomized trials, review articles, perspectives, community case studies or others. Studies linking basic research to clinical practice or translation to new therapies or diagnositic tools will be prioritized. Accepted articles are anticipated to span across a variety of clinical disciplines or sections. Single case reports will not be considered. In addition, manuscripts focusing on hEDS will be prioritized, especially those providing insight into frequently encountered co-morbid conditions; however, submissions related to any EDS subtype as well as Hypermobility Spectrum Disorder will be considered.
